Foundations Course in Cannabinoid Therapy

The Institute's flagship 12-module course in cannabinoid science, safety, evidence appraisal, clinical contexts and prescribing principles. The final three case-study modules are in development, with content being finalised.

• Explain foundational cannabinoid science, pharmacology and safety considerations.
• Appraise evidence and its limitations across selected products, formulations and clinical indications.

1. 01
   The Endocannabinoid System

   A widely distributed signalling system involved in the regulation of numerous physiological processes, providing important biological context for understanding the actions of cannabinoids. — Dr Shabnam Sarshar (Germany)

2. 02
   Medicinal Cannabis Overview

   The plant, major product types and lawful clinical contexts, with clear distinctions between historical use, biological plausibility and modern clinical evidence. — Prof Kylie O'Brien (Australia)

3. 03
   An Overview of Pharmacokinetics, Pharmacodynamics and Safety of Cannabis

   Absorption, distribution, metabolism and elimination of cannabinoids, together with adverse effects, contraindications and drug–drug interaction considerations. — Dr Mitchell Low (Australia)

4. 04
   Cannabidiol

   CBD pharmacology and safety, with appraisal of regulator-approved uses, controlled clinical trials and indications where evidence remains limited or inconsistent. — Dr Philip Blair (United States)

5. 05
   Minor Phytocannabinoids and Terpenes or Terpenoids in Cannabis

   CBG, CBC, CBN and cannabis terpenes, separating laboratory and preclinical findings from clinical evidence and critically examining the entourage hypothesis. — Dr Liam Engel (Australia)

6. 06
   An Overview of Chronic Pain and Medicinal Cannabis

   An appraisal of controlled trials, observational findings and limitations across particular cannabinoid products, formulations and chronic pain populations. — Educator to be announced

7. 07
   An Overview of Anxiety and Medicinal Cannabis

   Cannabinoid mechanisms and clinical research in anxiety, including limited or mixed evidence, formulation-specific findings and important safety cautions. — Prof Kylie O'Brien (Australia)

8. 08
   An Overview of Sleep Disorders and Medicinal Cannabis

   Sleep architecture and sleep disorders, with critical review of controlled, observational and insufficient evidence for specific cannabinoid formulations. — Educator to be announced

9. 09
   Principles of Medicinal Cannabis Prescribing

   Principles of patient assessment, product and formulation considerations, titration, monitoring and review within authorised professional scope and local law. — Educator to be announced

10. 10
    Case Studies in Chronic PainIn development · content being finalised

    Case-study content is being finalised. No cases, educators or sponsors are announced at this stage. — Educator to be announced

11. 11
    Case Studies in SleepIn development · content being finalised

    Case-study content is being finalised. No cases, educators or sponsors are announced at this stage. — Educator to be announced

12. 12
    Case Studies in AnxietyIn development · content being finalised

    Case-study content is being finalised. No cases, educators or sponsors are announced at this stage. — Educator to be announced